Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Capobianco

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 13, 2023
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders RegisterPaola Mosconi, Tommaso Guerra, Pasquale Paletta, et al.
Annals of Neurology|January 22, 2021
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple SclerosisMaria P Sormani, Nicola De Rossi, Irene Schiavetti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 17, 2020
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statementLucia Moiola, Valeria Barcella, Simone Benatti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 17, 2020
Vaccinations in patients with multiple sclerosis: A Delphi consensus statementAgostino Riva, Valeria Barcella, Simone V Benatti, et al.
Journal of Alzheimer'S Disease : JAD|December 3, 2024
Real-life reliability of plasma pTau181, Aβ<sub>42</sub>/Aβ<sub>40</sub>, and pTau181/Aβ<sub>42</sub> measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid statusDaniele Imperiale, Cristiana Atzori, Daniele Pio Angeloro, et al.
Journal of Neurology|June 19, 2019
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort studyJessica Frau, Francesco Saccà, Alessio Signori, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|November 12, 2020
E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disordersArlette L Bruijstens, Eva-Maria Wendel, Christian Lechner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 30, 2021
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort studyMaria Pia Sormani, Irene Schiavetti, Doriana Landi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 25, 2018
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational studyDamiano Baroncini, Mauro Zaffaroni, Lucia Moiola, et al.
Journal of Neuroimmunology|August 14, 2023
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumabAlessandra Sottini, Virginia Quaresima, Mosè Barbaro, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 13, 2023
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders RegisterPaola Mosconi, Tommaso Guerra, Pasquale Paletta, et al.
Annals of Neurology|January 22, 2021
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple SclerosisMaria P Sormani, Nicola De Rossi, Irene Schiavetti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 17, 2020
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statementLucia Moiola, Valeria Barcella, Simone Benatti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 17, 2020
Vaccinations in patients with multiple sclerosis: A Delphi consensus statementAgostino Riva, Valeria Barcella, Simone V Benatti, et al.
Journal of Alzheimer'S Disease : JAD|December 3, 2024
Real-life reliability of plasma pTau181, Aβ<sub>42</sub>/Aβ<sub>40</sub>, and pTau181/Aβ<sub>42</sub> measured by Lumipulse G600II in predicting cerebrospinal fluid amyloid statusDaniele Imperiale, Cristiana Atzori, Daniele Pio Angeloro, et al.
Journal of Neurology|June 19, 2019
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort studyJessica Frau, Francesco Saccà, Alessio Signori, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|November 12, 2020
E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disordersArlette L Bruijstens, Eva-Maria Wendel, Christian Lechner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 30, 2021
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort studyMaria Pia Sormani, Irene Schiavetti, Doriana Landi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 25, 2018
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational studyDamiano Baroncini, Mauro Zaffaroni, Lucia Moiola, et al.
Journal of Neuroimmunology|August 14, 2023
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumabAlessandra Sottini, Virginia Quaresima, Mosè Barbaro, et al.
Pageof 8